Correction to: Nature Communications https://doi.org/10.1038/s41467-022-32960-3, published online 09 September 2022

The original version of this Article had numerical mistakes in the source data corresponding to figure 1a, some values (or textual entries) were missing (cells 1P, 18P), and some were incorrect (cells 3Q, 4J, 11J-P, 17K-L, 18N, 30B, 30E, 30J-K, 30N, 39E, 39J, 40E, 40J, 41E, 54J, 63J-L, 65B, 65K, 65N, 73E, 73J, 74E, 74J, 78N-P, 85J). These are replaced with the correct entries.

Column B of the source data corresponding to Supplementary Table 1 is now deleted, due to confidentiality concerns.

Accordingly, the text of the “Clinical trial outcomes” section of the Results has been corrected:

Line 10: “Within 1 month after BCMA CAR-T cell infusion, 2 patients died of cerebral hemorrhage and 4 died of severe infections.

Of the 95 evaluable patients, 91 (95.8%) had an overall response.”

Line 13: “With a median follow-up time of 21.2 months (95% CI, 18.4–32.1), the median progression-free survival (PFS) was 12.0 (95% CI, 8.1–15.7) months. The 1-year OS and PFS rates were 0.70 (95% CI, 0.61–0.80) and 0.48 (95% CI, 0.39–0.59), respectively.